SILO PHARMA, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.06 USD | +0.97% |
|
-6.19% | -26.39% |
| 11/06 | Silo Pharma, Inc. announced that it has received $2.077409 million in funding | CI |
| 07/06 | Silo Pharma Close to Achieving Optimal Formulation for Ketamine Implant | MT |
| Sales 2022 | 0.07 6.01 | Sales 2023 | 0.07 6.01 | Capitalization | 44.66L 37Cr |
|---|---|---|---|---|---|
| Net income 2022 | -30L -25Cr | Net income 2023 | -30L -25Cr | EV / Sales 2022 | -1,14,25,411 x |
| Net cash position 2022 | 1.14Cr 95Cr | Net cash position 2023 | 76.65L 64Cr | EV / Sales 2023 | -4,43,68,852 x |
| P/E ratio 2022 |
-1.96
x | P/E ratio 2023 |
-1.2
x | Employees | 3 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 87.39% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +0.97% | ||
| 1 week | -6.19% | ||
| Current month | -49.04% | ||
| 1 month | -47.78% | ||
| 3 months | -40.78% | ||
| 6 months | -31.61% | ||
| Current year | -26.39% |
1 week
1.03
1.30
1 month
1.032.57
Current year
1.032.57
1 year
1.033.05
3 years
1.0314.90
5 years
1.0338.00
10 years
1.03125.00
| Managers | Title | Age | Since |
|---|---|---|---|
Eric Weisblum
CEO | Chief Executive Officer | 54 | 13/10/13 |
Daniel Ryweck
DFI | Director of Finance/CFO | 59 | 27/22/27 |
James Kuo
CTO | Chief Tech/Sci/R&D Officer | 58 | 01/22/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Eric Weisblum
CEO | Chief Executive Officer | 54 | 13/10/13 |
Wayne Linsley
BRD | Director/Board Member | 67 | 16/20/16 |
Kevin Muñoz
BRD | Director/Board Member | 46 | 01/20/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 18/24/18 | 1.06 | +0.97% | 3 797 |
| 17/24/17 | 1.05 | -4.56% | 104,018 |
| 14/24/14 | 1.1 | -9.09% | 203,582 |
| 13/24/13 | 1.21 | +9.50% | 618,595 |
| 12/24/12 | 1.105 | -2.21% | 148,948 |
Delayed Quote Nasdaq, June 18, 2024 at 07:10 pm IST
More quotes
Silo Pharma, Inc. is a developmental stage biopharmaceutical company. The Company is focused on developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It is engaged in acquiring and/or developing intellectual property or technology rights from universities and researchers to treat rare diseases, including the use of psychedelic drugs, such as psilocybin, and the potential benefits they may have in certain cases involving depression, mental health issues and neurological disorders. The Companyâs lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. Its SP-26 is a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. Its two preclinical programs are SPC-14, an intranasal compound for the treatment of Alzheimerâs disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS).
Sector
Pharmaceuticals
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -26.39% | 38.7L | |
| +2.52% | 9.21TCr | |
| -3.16% | 3.79TCr | |
| -12.29% | 3.3TCr | |
| +75.16% | 2.79TCr | |
| -11.41% | 1.61TCr | |
| +1.50% | 1.41TCr | |
| -11.18% | 1.17TCr | |
| +171.57% | 1.03TCr | |
| -50.45% | 998.92Cr |
- Stock Market
- Equities
- SILO Stock
